国邦医药
(605507)
| 流通市值：122.36亿 | | | 总市值：122.36亿 |
| 流通股本：7.82亿 | | | 总股本：7.82亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,142,428,542.07 | 1,520,880,277.95 | 6,011,397,499.1 | 4,469,884,398.26 |
| 营业收入 | 3,142,428,542.07 | 1,520,880,277.95 | 6,011,397,499.1 | 4,469,884,398.26 |
| 二、营业总成本 | 2,771,333,618.87 | 1,334,911,518.48 | 5,101,191,544.3 | 3,740,282,795.29 |
| 营业成本 | 2,395,350,161.87 | 1,170,110,951.38 | 4,446,532,644.49 | 3,267,396,642.23 |
| 税金及附加 | 26,960,865.53 | 14,476,360.76 | 48,473,839.65 | 38,557,145.8 |
| 销售费用 | 54,063,373.95 | 21,616,618.55 | 97,693,315.31 | 61,270,072.05 |
| 管理费用 | 151,387,019.32 | 76,259,290.97 | 278,009,950.28 | 213,228,695.39 |
| 研发费用 | 98,310,697.6 | 29,721,902.93 | 209,832,449.33 | 153,437,892.4 |
| 财务费用 | 45,261,500.6 | 22,726,393.89 | 20,649,345.24 | 6,392,347.42 |
| 其中:利息费用 | 11,170,931.1 | 9,192,104.64 | 23,919,143.28 | 17,054,357.06 |
| 其中:利息收入 | 4,629,112.93 | 4,028,925.73 | 17,568,165.07 | 14,782,755.29 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,042,965.83 | 4,430,211.48 | 12,922,936.6 | 7,293,137.28 |
| 加:投资收益 | 7,060,366.3 | 2,708,925.71 | 16,992,661.8 | 13,206,124.44 |
| 资产处置收益 | - | - | 24,812,057.81 | 23,885,362.6 |
| 资产减值损失(新) | -3,970,311.96 | -3,244,344.94 | -27,022,156.04 | -10,690,981.67 |
| 信用减值损失(新) | -3,961,509.42 | -9,694,930.42 | -4,944,075.91 | -7,539,464.45 |
| 其他收益 | 12,443,871.97 | 7,771,458.49 | 31,026,572.57 | 23,682,944.83 |
| 四、营业利润 | 390,710,305.92 | 187,940,079.79 | 963,993,951.63 | 779,438,726 |
| 加:营业外收入 | 2,025,294.49 | 2,780,707.98 | 1,703,118.44 | 2,214,595.59 |
| 减:营业外支出 | 4,898,191.74 | 3,547,369 | 14,437,158.32 | 6,775,636.56 |
| 五、利润总额 | 387,837,408.67 | 187,173,418.77 | 951,259,911.75 | 774,877,685.03 |
| 减:所得税费用 | 46,514,934.54 | 27,044,785.21 | 133,686,199.25 | 106,990,259.26 |
| 六、净利润 | 341,322,474.13 | 160,128,633.56 | 817,573,712.5 | 667,887,425.77 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 341,322,474.13 | 160,128,633.56 | 817,573,712.5 | 667,887,425.77 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 341,348,063.99 | 160,629,674.68 | 820,820,433.45 | 670,242,636.55 |
| 少数股东损益 | -25,589.86 | -501,041.12 | -3,246,720.95 | -2,355,210.78 |
| 扣除非经常损益后的净利润 | 320,663,595.68 | 150,601,053.3 | 770,351,486.8 | 619,188,714.53 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.44 | 0.29 | 1.48 | 1.21 |
| (二)稀释每股收益 | 0.44 | 0.29 | 1.48 | 1.21 |
| 九、综合收益总额 | 341,322,474.13 | 160,128,633.56 | 817,573,712.5 | 667,887,425.77 |
| 归属于母公司股东的综合收益总额 | 341,348,063.99 | 160,629,674.68 | 820,820,433.45 | 670,242,636.55 |
| 归属于少数股东的综合收益总额 | -25,589.86 | -501,041.12 | -3,246,720.95 | -2,355,210.78 |
| 公告日期 | 2026-08-01 | 2026-04-16 | 2026-03-28 | 2025-10-17 |
| 审计意见(境内) | | | 标准无保留意见 | |